{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:19:38Z","timestamp":1794507578151,"version":"4.9.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,4]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or hotspot areas of 68 recurrently mutated genes in a cohort of 664 patients aged 18 to 86 years treated on 2 phase 3 trials of the German AML Cooperative Group (AMLCG). The median number of 4 mutations per patient varied according to cytogenetic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy. We found patterns of significantly comutated driver genes suggesting functional synergism. Conversely, we identified 8 virtually nonoverlapping patient subgroups, jointly comprising 78% of AML patients, that are defined by mutually exclusive genetic alterations. These subgroups, likely representing distinct underlying pathways of leukemogenesis, show widely divergent outcomes. Furthermore, we provide detailed information on associations between gene mutations, clinical patient characteristics, and therapeutic outcomes in this large cohort of uniformly treated AML patients. In multivariate analyses including a comprehensive set of molecular and clinical variables, we identified DNMT3A and RUNX1 mutations as important predictors of shorter overall survival (OS) in AML patients &amp;lt;60 years, and particularly in those with intermediate-risk cytogenetics. NPM1 mutations in the absence of FLT3-ITD, mutated TP53, and biallelic CEBPA mutations were identified as important molecular prognosticators of OS irrespective of patient age. In summary, our study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood-2016-01-693879","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T05:22:31Z","timestamp":1465622551000},"page":"686-698","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":493,"title":["Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus H.","family":"Metzeler","sequence":"first","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-9432","authenticated-orcid":false,"given":"Tobias","family":"Herold","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Rothenberg-Thurley","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Amler","sequence":"additional","affiliation":[{"name":"4Institute of Biostatistics and Clinical Research, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Sauerland","sequence":"additional","affiliation":[{"name":"4Institute of Biostatistics and Clinical Research, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"G\u00f6rlich","sequence":"additional","affiliation":[{"name":"4Institute of Biostatistics and Clinical Research, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola P.","family":"Konstandin","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Dufour","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Br\u00e4undl","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Ksienzyk","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Zellmeier","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Hartmann","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Greif","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fiegl","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Bohlander","sequence":"additional","affiliation":[{"name":"5Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine 3, Klinikum Leverkusen, Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Faldum","sequence":"additional","affiliation":[{"name":"4Institute of Biostatistics and Clinical Research, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[{"name":"7Department of Medicine A, Hematology and Oncology, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Hematology, Oncology, Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcchner","sequence":"additional","affiliation":[{"name":"7Department of Medicine A, Hematology and Oncology, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Braess","sequence":"additional","affiliation":[{"name":"9Department of Oncology and Hematology, Hospital Barmherzige Br\u00fcder, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[{"name":"1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universit\u00e4t, Munich, Germany"},{"name":"2German Cancer Consortium (DKTK), Heidelberg, Germany"},{"name":"3German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7218","key":"2024060721364096800_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"issue":"25","key":"2024060721364096800_bib2","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia.","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2024060721364096800_bib3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome.","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"2024060721364096800_bib4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2024060721364096800_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"2024060721364096800_bib6","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","article-title":"Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.","volume":"24","author":"B\u00fcchner","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"2024060721364096800_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.619.619","article-title":"High efficacy and significantly shortened neutropenia of dose-dense S-HAM as compared to standard double induction: first results of a prospective randomized trial (AML-CG 2008) [abstract].","volume":"122","author":"Braess","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024060721364096800_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/leu.2016.25","article-title":"Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.","volume":"30","author":"Krug","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2024060721364096800_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"Database issue","key":"2024060721364096800_bib10","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer.","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2024060721364096800_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2141.2008.07328.x","article-title":"Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.","volume":"143","author":"Benthaus","year":"2008","journal-title":"Br J Haematol"},{"issue":"21","key":"2024060721364096800_bib12","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2008-09-172668","article-title":"NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).","volume":"113","author":"Schneider","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2024060721364096800_bib13","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024060721364096800_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2024060721364096800_bib15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2013-12-540716","article-title":"Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.","volume":"124","author":"Herold","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024060721364096800_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ajhg.2015.12.021","article-title":"MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations.","volume":"98","author":"Hua","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2024060721364096800_bib17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","article-title":"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.","volume":"30","author":"Marcucci","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2024060721364096800_bib18","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2024060721364096800_bib19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.","volume":"28","author":"Kihara","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2024060721364096800_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"2024060721364096800_bib21","doi-asserted-by":"crossref","first-page":"7422","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"1000 Genomes Project Consortium","year":"2012","journal-title":"Nature"},{"issue":"9","key":"2024060721364096800_bib22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2024060721364096800_bib23","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","article-title":"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.","volume":"118","author":"Metzeler","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2024060721364096800_bib24","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","article-title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.","volume":"30","author":"Mendler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024060721364096800_bib25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024060721364096800_bib26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2011.39.2886","article-title":"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.","volume":"30","author":"Gaidzik","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024060721364096800_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.","volume":"29","author":"Metzeler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024060721364096800_bib28","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2024060721364096800_bib29","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024060721364096800_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2024060721364096800_bib31","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.2014.59.2022","article-title":"Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.","volume":"33","author":"Gale","year":"2015","journal-title":"J Clin Oncol"},{"issue":"149","key":"2024060721364096800_bib32","doi-asserted-by":"crossref","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7488","key":"2024060721364096800_bib33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2024060721364096800_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"issue":"31","key":"2024060721364096800_bib35","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1073\/pnas.0903091106","article-title":"Acquired copy number alterations in adult acute myeloid leukemia genomes.","volume":"106","author":"Walter","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2024060721364096800_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2012-01-403220","article-title":"GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.","volume":"120","author":"Greif","year":"2012","journal-title":"Blood"},{"key":"2024060721364096800_bib37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-705053","article-title":"Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.","author":"Lavall\u00e9e","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2024060721364096800_bib38","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2024060721364096800_bib39","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2024060721364096800_bib40","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2024060721364096800_bib41","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","article-title":"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).","volume":"121","author":"Gaidzik","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2024060721364096800_bib42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"2024060721364096800_bib43","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2024060721364096800_bib44","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations.","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2024060721364096800_bib45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2015.288","article-title":"Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.","volume":"30","author":"Wakita","year":"2016","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1182\/blood.2024025758","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/128\/5\/686\/2228721\/blood-34287-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/128\/5\/686\/2228721\/blood-34287-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:37:18Z","timestamp":1717796238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/5\/686\/35562\/Spectrum-and-prognostic-relevance-of-driver-gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-693879","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2024025758","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}